AI & NAM Technologies

Despite its promise, AI currently has limited impact on this high-risk stage. The underlying reason is the sheer complexity of human biology. This variability is influenced by gene expression, environmental factors, and complex biological interactions that remain difficult to model. Compounding the challenge is the nature of available data. Biomedical data is often insufficient, fragmented, and siloed across institutions, making it difficult for AI systems to learn effectively. While AI can identify trends and predict average responses across populations, successful therapies must ultimately work on an individual level — a gap that still is very challenging to bridge.

In response to these limitations, new innovation efforts are emerging. At abc biopply, our team has developed a novel Multi-Organoid NAM technology designed to generate richer, more integrated biological datasets. By producing thousands of data points from a single source, this approach significantly improves the ability to capture variability on the level of the individual-leel.

The platform combines advanced NAM technology with AI training, leveraging AI where it performs best—identifying patterns within large, image-based datasets. It enables a one-to-one correlation between morphology and behavior by integrating multi-omics profiling from a single source. The resulting datasets provide more robust phenotypic statistics and greater relevance for AI models. Early results indicate that such data-driven approaches can accelerate development timelines and enhance predictive accuracy, addressing two of the most critical bottlenecks in drug development.

As the pharmaceutical industry continues to invest heavily in AI, the focus may increasingly shift from pure efficiency gains to improving biological understanding and data quality. Innovations like multi-organoid systems could play a crucial role in unlocking AI’s full potential — moving it beyond workflow optimization and toward truly predictive and individualized medicine.